"* Most Insurance Welcomed* On Call 24 Hours Every Day* Vitreo- Retinal Consultants & Surgeons P.A.Doctors:* Dalla, Kumar P* Weishaar, Paul D* Varenhorst, Michael P"

During the past decade, Vitreo-Retinal Consultants & Surgeons conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Vitreo-Retinal Consultants & Surgeons" are "Geographic Atrophy" (1 trials), "Macular Degeneration" (1 trials), "Symptomatic Vitreomacular Adhesion" (1 trials) and "Wet Age-related Macular Degeneration" (1 trials). Many other conditions were trialed in "Vitreo-Retinal Consultants & Surgeons" in a lesser frequency.

Most popular intervention types in "Vitreo-Retinal Consultants & Surgeons" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Zimura" (2 trials), "Lucentis" (1 trials) and "Sham" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vitreo-Retinal Consultants & Surgeons" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Vitreo-Retinal Consultants & Surgeons". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Vitreo-Retinal Consultants & Surgeons, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Vitreo-Retinal Consultants & Surgeons, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".